State of the Art and Future Perspectives for the Use of Insulin-like Growth Factor Receptor 1 (IGF-1R) Targeted Treatment Strategies in Solid Tumors

被引:0
作者
Scartozzi, Mario [1 ]
Bianconi, Maristella [1 ]
Maccaroni, Elena [1 ]
Giampieri, Riccardo [1 ]
Del Prete, Michela [1 ]
Berardi, Rossana [1 ]
Cascinu, Stefano [1 ]
机构
[1] AO Osped Riuniti, Clin Oncol Med, Ancona, Italy
关键词
FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY CP-751,871; PHASE-I; DOSE-ESCALATION; PLASMA-LEVELS; CANCER RISK; BREAST; EXPRESSION; CELLS; MECHANISMS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Insulin-like growth factor receptor 1 (IGF-1R) with its ligands and intracellular pathway is involved in cell growth and survival control. Many studies have shown how IGF-1R is over-expressed in various tumor cell lines and histological samples. In recent years many trials have been conducted investigating IGF-1R as a possible cancer therapy, with major efforts focusing on the use of monoclonal antibodies and small molecules directed against the IGF-1R-driven pathway. Several drugs are currently under intense investigation and in different experimental phases. Available data suggest that this class of drugs is well tolerated with mild to moderate side effects, when used alone or in combination with other therapeutic agents. The efficacy profile seems to be promising. However, further studies are needed to define the exact role of IGF-1R inhibitors in clinical practice. [Discovery Medicine 11(57):144-153, february 2011]
引用
收藏
页码:144 / 153
页数:10
相关论文
共 79 条
[1]  
[Anonymous], J CLIN ONCOL
[2]   A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [J].
Atzori, F. ;
Tabernero, J. ;
Cervantes, A. ;
Botero, M. ;
Hsu, K. ;
Brown, H. ;
Hanley, W. ;
Macarulla, T. ;
Rosello, S. ;
Baselga, J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[3]  
BASERGA R, 1995, CANCER RES, V55, P249
[4]   The IGF-I receptor and cancer [J].
Baserga, R ;
Resnicoff, M ;
Dews, M .
ENDOCRINE, 1997, 7 (01) :99-102
[5]   The igf-1 receptor in cancer biology [J].
Baserga, R ;
Peruzzi, F ;
Reiss, K .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) :873-877
[6]   The role of insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer [J].
Belfiore, Antonino .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (07) :671-686
[7]   Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma [J].
Benini, Stefania ;
Zuntini, Monia ;
Manara, Maria Cristina ;
Cohen, Pinchas ;
Nicoletti, Giordano ;
Nanni, Patrizia ;
Oh, Youngman ;
Picci, Piero ;
Scotlandi, Katia .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) :1039-1046
[8]   Type-2 IGF receptor: A multi-ligand binding protein [J].
Braulke, T .
HORMONE AND METABOLIC RESEARCH, 1999, 31 (2-3) :242-246
[9]  
Britten C, 2008, EUR J CANC, V6
[10]   Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors [J].
Buck, Elizabeth ;
Eyzaguirre, Alexandra ;
Rosenfeld-Franklin, Maryland ;
Thomson, Stuart ;
Mulvihill, Mark ;
Barr, Sharon ;
Brown, Eric ;
O'Connor, Mathew ;
Yao, Yan ;
Pachter, Jonathan ;
Miglarese, Mark ;
Epstein, David ;
Iwata, Kenneth K. ;
Haley, John D. ;
Gibson, Neil W. ;
Ji, Qun-Sheng .
CANCER RESEARCH, 2008, 68 (20) :8322-8332